I think once the generic hits the market that many those switched to thrice weekly will go to the generic because of cost.
Also, if TEVA were to hit that 50% mark with thrice weekly with a generic approved, what would stop the company with the generic from going for the thrice weekly generic?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.